Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,289 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物关于召开2025年度暨2026年第一季度业绩说明会的公告
Regulatory Filings Classification · 85% confidence The document is a formal announcement by the company to convene a 2025 full-year and 2026 Q1 performance briefing (业绩说明会) for investors, detailing time, venue, participation method and contact info. It does not contain the actual financial report or the presentation materials, nor is it a transcript or an earnings summary—it’s simply a general regulatory announcement about an upcoming investor event. This does not fit any specific categories like Investor Presentation (which requires the slide deck), Earnings Release (which would summarize results), or Call Transcript. Therefore it falls under the fallback “Regulatory Filings” category.
2026-05-22 Chinese
安图生物2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 96% confidence The document is a public announcement by the company’s board detailing the per-share cash dividend amount for the 2025 fiscal year, the record date, ex-dividend date, payment date, total payout, and tax arrangements. It does not contain full financial statements or serve as an AGM/EGM notice beyond approving the dividend, nor is it an interim/annual report, audit report, or share issuance. This matches the definition of a Notice of Dividend Amount (DIV).
2026-05-21 Chinese
安图生物关于公司及全资子公司获得医疗器械注册证的公告
Regulatory Filings Classification · 82% confidence The document is a stock exchange regulatory announcement in Chinese by Zhengzhou Antu Bioengineering Co., Ltd. regarding the receipt of medical device registration certificates. It contains no financial statements, management changes, or shareholder actions. It is a general compliance/regulatory announcement and does not fit any specific category such as earnings, dividends, or capital activities. Therefore, it falls under the fallback category “Regulatory Filings” (RNS).
2026-05-19 Chinese
安图生物2025年年度股东会法律意见书
Regulatory Filings Classification · 78% confidence The document is a legal opinion letter issued by Shanghai AllBright Law Offices regarding the legality of procedures and voting results at the company’s 2025 Annual General Meeting. It is not the AGM materials themselves (AGM-R), nor is it an announcement that a report is available (RPA). It is not a financial report or earnings release, nor a proxy solicitation. It primarily provides a legal attestation of compliance and votes, so it falls into the general “Regulatory Filings” fallback category (RNS).
2026-05-13 Chinese
安图生物2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 2025 Annual General Meeting, detailing attendance, each proposal considered, and the share‐by‐share voting results. It is a formal declaration of voting outcomes at an AGM, matching the “Declaration of Voting Results” category.
2026-05-13 Chinese
安图生物2025年年度股东会会议材料
Regulatory Filings
2026-05-07 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.